Amivantamab IV Injection (Rybrevant) administration and management
This is an in-service lecture fot the CUHK Medical Centre Pharmacy Staff
Upon completion of the activity, participants will learn:
- The specific types of lung cancer for which Amivantamab is approved and the rationale behind its use (Advance NSCLC patients with EGFR ex20 insertion)
- The mechanism of action of Amivantamab and its role in the evolving landscape of lung cancer treatment
- The recommended dosing regimen and route of administration
- The potential side effects associated with Amivantamab and strategies for managing them effectively
Date:
2024-07-23
Time:
1:00pm to 2:00pm
Venue:
L3 Pharmacy Service, CUHK Medical Centre, 9 Chak Cheung Street, Shatin
Organising Institute:
Johnson and Johnson (Hong Kong) Ltd.
Speaker:
Dennis Ho
Business Manager, J & J Innovative Medicine, Oncology Business Unit
BSc, Cert.Med. Rep. (HKAPI)
Related CPE Activities:
